Phase 2 Apecotrep Delivers 40% Proteinuria Reduction in FSGS

Apecotrep is an investigational oral small-molecule TRPC5 channel inhibitor being developed for focal segmental glomerulosclerosis (FSGS); early reports describe a clinically meaningful reduction in proteinuria in a phase 2 setting, consistent with the established role of the TRPC5–Rac1 pathway in driving podocyte injury and proteinuria.